Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Chaccour, 2020
 
NCT04390022
RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 outpatients meta-analysis

COPE – Coalition V, 2022
 
NCT04466540
RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
689/683 inconclusive
  • inconclusive 23 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
TOGETHER (ivermectine), 2022
 
NCT04727424
RCTivermectinplaceboCOVID 19 outpatientslow
679/679 inconclusive
  • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
ACTION, 2021
 
NCT04332107
RCTazithromycinplaceboCOVID 19 outpatientssome concern
171/92 inconclusive
  • inconclusive 1 % increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
The original primary outcome was changed given the lower risk of hospitalization and slower than anticipated enrollment.
EPIC-HR, 2021
 
NCT04960202
RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 outpatientslow
1120/1126 conclusif
  • demonstrated 88 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 96 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
  • suggested 90 % decrease in hospitalization or death with a high degree of certainty due to low risk of bias
  • suggested 88 % decrease in hospitalization or death with a high degree of certainty due to low risk of bias
  • statistically significant 76 % increase in related AE (TRAE) with a high degree of certainty due to low risk of bias
Based on laboratory studies only, Paxlovid is also expected to be active against Omicron and other variants.
Fischer (all doses), 2021
 
NCT04405570
RCTmolnupiravirplaceboCOVID 19 outpatientssome concern
140/62 suggested
  • suggested 13.5-fold increase in viral clearance ,viral clearance by day 7 with a moderate degree of certainty due to some concern in risk of bias
Hinks (ATOMIC2), 2021
 
NCT04381962
RCTazithromycinstandard of careCOVID 19 outpatientssome concern
147/148 inconclusive
  • inconclusive 9 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
Lopez-Medina, 2021
 
NCT04405843
RCTivermectinplaceboCOVID 19 outpatientssome concern
200/200 inconclusive
  • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
MOVe-OUT, 2021
 
NCT04575597
RCTmolnupiravirplaceboCOVID 19 outpatientslow
716/717 conclusif
  • demonstrated 52 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 51 % decrease in hospitalization with a high degree of certainty due to low risk of bias
PATCH Cohort 1 (Amaravadi), 2021
 
NCT04329923
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
15/13 inconclusive
    PINETREE (GS-US-540-9012), 2021
     
    NCT04501952
    RCTremdesivirplaceboCOVID 19 outpatientslow
    292/292 conclusif
    • demonstrated 87 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
    • suggested 72 % decrease in hospitalization with a high degree of certainty due to low risk of bias
    PRINCIPLE, 2021
     
    ISRCTN86534580
    RCTazithromycinstandard of careCOVID 19 outpatientssome concern
    540/875 inconclusive
    • inconclusive 8 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 6 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
    Reis (Hydroxychloroquine) (TOGETHER), 2021
     
    NCT04403100
    RCTlopinavir/ritonavirplaceboCOVID 19 outpatientssome concern
    214/227 inconclusive
      Reis (Lopinavir-ritonavir) (TOGETHER), 2021
       
      NCT04403100
      RCTlopinavir/ritonavirplaceboCOVID 19 outpatientssome concern
      244/227 inconclusive
        Rodrigues, 2021 RCTazithromycin plus hydroxychloroquineplaceboCOVID 19 outpatientssome concern
        42/42 inconclusive
          TOGETHER, 2021
           
          NCT04727424
          RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
          741/756 suggested
          • suggested 36 % decrease in emergency room observation for > 6 hours or hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
          BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020
           
          NCT04304053
          RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
          137/157 safety concern
          • statistically significant 25.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 177.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          COVID-PEP Severity (Skipper), 2020
           
          NCT04308668
          RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
          244/247 no results
            change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
            COVID-PEP Severity (Skipper), 2020
             
            NCT04308668
            RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
            244/247 safety concern
            • statistically significant 1.8-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
            change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
            IVERCORCOVID19 (Vallejos), 2020
             
            NCT04529525
            RCTivermectinplaceboCOVID 19 outpatientslow
            250/251 inconclusive
            • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
            Lenze (STOP COVID 1), 2020
             
            NCT04342663
            RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
            80/72 conclusif
            • demonstrated 93 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
            Q-PROTECT (HCQ/AZI vs PLACEBO), 2020
             
            NCT04349592
            RCThydroxychloroquine plus macrolidesplaceboCOVID 19 outpatientssome concern
            152/152 safety concern
            • inconclusive 14 % decrease in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
            • statistically significant 45 % decrease in viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
            Roozbeh, 2020
             
            IRCT20200403046926N1
            RCTsofosbuvir and daclatasvirstandard of careCOVID 19 outpatients
            bias due to missing outcome data some concern
            bias in measurement of the primary outcome some concern
            bias in selection of the reported result some concern
            " >some concern
            30/30 inconclusive 11 studies excluded by filtering options (8 RCT / 3 OBS)

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).